Literature DB >> 23960785

A validated capillary electrophoresis method for simultaneous determination of ezetimibe and atorvastatin in pharmaceutical formulations.

Mona M Alshehri1.   

Abstract

A simple, precise, and sensitive capillary electrophoresis technique coupled with a diode array detector has been developed for the separation and simultaneous determination of ezetimibe and atorvastatin in pharmaceutical formulations. Separation of both ezetimibe and atorvastatin was achieved utilizing fused silica capillary (58 cm × 75 μm ID) and background electrolyte solution that consisted of phosphate buffer (2.5 mM, pH 6.7): methanol (70:30 v/v). The proposed method was validated by testing its specificity, linearity, precision, accuracy, recovery, and detection limit/quantitation limit values. The method was linear over the range 2.5-50 μg/ml for ezetimibe (r = 0.9992) and 1-100 μg/ml for atorvastatin (r = 0.9999). Within-day and between-day RSD for ezetimibe and atorvastatin were ⩽5.6% and ⩽2.9%, respectively. The detection limit was 0.07 μg/ml for ezetimibe and 0.06 μg/ml for atorvastatin. The validated method was successfully employed for the determination of ezetimibe and atorvastatin in tablets with no interfering peaks from common pharmaceutical excipients. The percentage recoveries of the two drugs from their tablets were 99.80 ± 1.76 and 100.19 ± 1.83, respectively.

Entities:  

Keywords:  Atorvastatin; Capillary electrophoresis; Diode array detector; Ezetimibe; Tablets

Year:  2011        PMID: 23960785      PMCID: PMC3745071          DOI: 10.1016/j.jsps.2011.09.005

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


  9 in total

Review 1.  Effects of organic solvents on sample pretreatment and separation performances in capillary electrophoresis.

Authors:  Carmen W Huie
Journal:  Electrophoresis       Date:  2003-05       Impact factor: 3.535

Review 2.  The preparation of background electrolytes in capillary zone electrophoresis: golden rules and pitfalls.

Authors:  Jozef L Beckers; Petr Bocek
Journal:  Electrophoresis       Date:  2003-01       Impact factor: 3.535

Review 3.  Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption.

Authors:  Eric Bruckert; Philippe Giral; Philippe Tellier
Journal:  Circulation       Date:  2003-07-01       Impact factor: 29.690

4.  Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia.

Authors:  C M Ballantyne; L J Lipka; P T Sager; J Strony; J Alizadeh; R Suresh; E P Veltri
Journal:  Int J Clin Pract       Date:  2004-07       Impact factor: 2.503

5.  Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.

Authors:  Scott E Conard; Harold E Bays; Lawrence A Leiter; Steven R Bird; Joseph Rubino; Robert S Lowe; Joanne E Tomassini; Andrew M Tershakovec
Journal:  Am J Cardiol       Date:  2008-10-23       Impact factor: 2.778

6.  Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.

Authors:  Lawrence A Leiter; Harold Bays; Scott Conard; Steven Bird; Joseph Rubino; Mary E Hanson; Joanne E Tomassini; Andrew M Tershakovec
Journal:  Am J Cardiol       Date:  2008-10-23       Impact factor: 2.778

7.  Enhanced spectrophotometric determination of two antihyperlipidemic mixtures containing ezetimibe in pharmaceutical preparations.

Authors:  Hadir M Maher; Rasha M Youssef; Ekram M Hassan; Eman I El-Kimary; Magda A Barary
Journal:  Drug Test Anal       Date:  2010-09-01       Impact factor: 3.345

Review 8.  Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.

Authors:  A P Lea; D McTavish
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

9.  Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.

Authors:  Christie M Ballantyne; John Houri; Alberto Notarbartolo; Lorenzo Melani; Leslie J Lipka; Ramachandran Suresh; Steven Sun; Alexandre P LeBeaut; Philip T Sager; Enrico P Veltri
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

  9 in total
  3 in total

1.  New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets.

Authors:  Tarek S Belal; Hoda G Daabees; Magdi M Abdel-Khalek; Mohamed S Mahrous; Mona M Khamis
Journal:  J Pharm Anal       Date:  2012-10-31

2.  Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization.

Authors:  Noha N Atia; Hesham M Tawfeek; Azza H Rageh; Marwa R El-Zahry; Ahmed Abdelfattah; Mahmoud A Younis
Journal:  Saudi Pharm J       Date:  2019-02-05       Impact factor: 4.330

3.  Performance evaluation of a novel potentiometric membrane sensor for determination of atorvastatin in pharmaceutical preparations.

Authors:  Farhad Ahmadi; Nasim Asaadi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.